
    
      This is a multicentre single arm clinical trial conducted in China,the purpose of this study
      is To Evaluate the Effectiveness and Safety of Anlotinib (12mg QD PO d1-14, 21 days per
      cycle)Combined with Docetaxel (75mg/m2 IV d1) for advanced non-small cell lung cancer after
      the failure of Platinum-Based Doublet-Chemotherapy.According to the result of TAX317,the ORR
      of second line standard chemotherapy was 5- 8%. We expect the ORR was 20%. Using PASS11, we
      calculated the sample size of this study was 41 , according to 10% censoring,the expected
      sample size is 46.
    
  